On February 8, 2022 Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, reported the closing of its initial public offering of 9,487,500 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,237,500 additional shares of its common stock, at a public offering price of $15.00 per share (Press release, Arcellx, FEB 8, 2022, View Source [SID1234607896]). The aggregate gross proceeds from the offering were $142.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by Arcellx. All of the shares of common stock were offered by Arcellx. Arcellx’s common stock began trading on the Nasdaq Global Select Market on February 4, 2022, under the ticker symbol "ACLX."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BofA Securities, SVB Leerink, Barclays and William Blair acted as joint book-running managers for the offering.

A registration statement relating to the offering has been filed with the Securities and Exchange Commission and became effective on February 3, 2022. The offering was made only by means of a prospectus, copies of which may be obtained from: BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at [email protected]; SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at 1-800-808-7525, ext. 6105, or by email at [email protected]; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at [email protected] or by telephone at (888) 603-5847; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at 1-800-621-0687, or by email at [email protected]. Copies of the final prospectus related to the offering are available at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

On February 8, 2022 Catalyst Clinical Research, a leading provider of clinical research services, and Ledger Run, a leading innovator in clinical operations technology, reported that it will partner to create streamlined clinical trial business processes to enhance and accelerate global studies (Press release, Catalyst Clinical Research, FEB 8, 2022, View Source [SID1234607815]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ledger Run will expand its partnership with Catalyst Oncology, Catalyst Clinical Research’s full-service, niche oncology CRO solution. Catalyst Oncology has implemented a proprietary Ledger Run platform known as ClinRunTM to improve site budget and payment capabilities. The expanded partnership will allow Catalyst to take advantage of the fully integrated capabilities of ClinRun by adding contracting and forecasting solutions.

"Ledger Run is a great strategic partner for Catalyst because the company provides a unique combination of innovative technology solutions and professional services," said Nick Dyer, CEO at Catalyst. "Their ClinRun integrated platform and first-class support have helped us overcome the operational challenges of complex oncology studies and deliver real value to our customers and investigative sites."

Focusing on next-generation cancer therapies, Catalyst Oncology provides skilled management of immuno-oncology and targeted therapies as well as expert oversight of complex studies to deliver customized clinical research solutions exclusively for the biotech market. Ledger Run’s ClinRun platform helps with budgeting, contracting, making payments, and forecasting. The software suite also automates manual tasks, reduces errors, and speeds cycle times while promoting engagement with investigator sites.

"Catalyst is doing remarkable work in oncology," said Gary Lubin, Chief Executive Officer at Ledger Run. "They are managing very complicated trials, often with challenging protocol designs.

"We are thrilled that Catalyst has selected us to help manage their critical clinical business operations and embraced our responsibility as a trusted business partner," Lubin added. "We are confident that our smart technologies and services will create value for their customers."

On February 8, 2022 Corcept Therapeutics Incorporated (NASDAQ: CORT) reported it will report fourth quarter and full-year 2021 financial results and provide a corporate update on February 15, 2022 (Press release, Corcept Therapeutics, FEB 8, 2022, https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-announce-fourth-quarter-and-full-year-2021 [SID1234607843]). The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information
To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time.

Click to Join Meeting

Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call. The passcode will be 1861918.

A replay will be available through February 22, 2022, at 1-855-859-2056 from the United States and 1-404-537-3406 internationally. The passcode will be 1861918. You may also access a replay on the Investors / Past Events tab of www.corcept.com

On February 8, 2022 BostonGene Corporation reported expanded capabilities of the BostonGene Tumor Portrait TM Test that enable healthcare providers and insurance companies to determine eligibility and predict response for immunotherapy treatment and manage the total cost of care for cancer patients (Press release, BostonGene, FEB 8, 2022, View Source [SID1234607859]). A sophisticated analysis of the tumor and tumor microenvironment (TME), the BostonGene Tumor Portrait TM Test, reveals critical drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BostonGene Tumor PortraitTM Test is highly predictive of response to immunotherapy and stratifies patients into responders and non-responders. This information will aid physicians with therapy selection, decrease unnecessary adverse events, and allow healthcare systems to reduce expenditures significantly. For patients classified as non-responders to immunotherapy, the BostonGene Tumor PortraitTM Test provides other potential therapy options, utilizing existing guidelines to equip the treating physician in selecting the ideal therapy route.

The BostonGene Tumor PortraitTM Test is based on results from its landmark research study published in the June 2021 edition of Cancer Cell. The manuscript, "Conserved pan-cancer microenvironment subtypes predict response to immunotherapy," details a transcriptomic-based tumor classification platform that identifies distinct TME subtypes, predicting prognosis and response to immune checkpoint blockade. The study, supported by BostonGene’s 80 granted and 70 pending U.S. and international patents on cancer immunity, represents the importance of innovative multi-platform analytics to improve patient outcomes. The BostonGene Tumor PortraitTM Test builds on the understanding that matching patients to therapy options based on genomic and transcriptomic characteristics can produce better outcomes and adds a unique feature of therapy response prediction to assist in selecting the right therapy for each patient. Presently, there is a challenge between identifying candidates for a particular class of drugs and the low response rate to selected therapies. This is a costly burden on the healthcare system and may cause unnecessary adverse events to patients.

"Immuno-oncology focuses on data-informed, more precise methods to select the best choice of treatments for patients the first time, minimizing side effects and costly trial and error," says Mark Poznansky, MD, Ph.D., Professor of Medicine, Harvard Medical School, Director of Vaccine and Immunotherapy Center, Massachusetts General Hospital and an academic research collaborator with BostonGene. "Technologies that can help predict treatment response create an opportunity to improve patient outcomes and reduce the cost of overall care."

"Oncologists can choose from several hundred unique FDA-approved drugs," says Nathan Fowler, MD, Chief Medical Officer at BostonGene. "Despite these options, cures are rare, and most patients with advanced disease will have limited response to single agents. Correctly identifying and selecting the best drug, or combination of drugs for each patient with the BostonGene test has the potential to increase cures for all cancer patients dramatically."

On February 8, 2022 Cerus Corporation (Nasdaq: CERS) reported that its fourth quarter and full-year 2021 financial results will be released on Tuesday, February 22, 2022, after the close of the stock market (Press release, Cerus, FEB 8, 2022, View Source [SID1234607816]). The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at View Source Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international).

A replay will be available on Cerus’ website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 8851919. The replay will be available approximately three hours after the call through March 8, 2022.